| HOME >> BIOLOGY >> TECHNOLOGY |
Supplemental disclosures of cash flow
information:
Income taxes paid 166 63 623
======== ========= =========
Interest paid -- -- 350
======== ========= =========
(*) Incorporation date see note 1.
XTL Biopharmaceuticals Ltd.
(A Development Stage Company)
Notes to Interim Consolidated Financial Statements
as of June 30, 2007 unaudited)
1. GENERAL
XTL Biopharmaceuticals Ltd. (the "Company") was incorporated under the Israel Companies Ordinance on March 9, 1993. The Company is a development stage company in accordance with Statement of Financial Accounting Standards ("SFAS") No. 7 "Accounting and Reporting by Development Stage Enterprises."
Through June 30, 2007, the Company has incurred losses in an aggregate amount of US $129.6 million. Such losses have resulted from the Company's activities as a development stage company. It is expected that the Company will be able to finance its operations from its current reserves through 2007. Continuation of the Company's current operations after utilizing its current cash reserves is dependent upon the generation of additional financial resources either through agreements for the commercialization of its product portfolio or through external financing. These matters raise substantial doubt about the Company's ability to continue as a going concern.
The Company has not generated any revenues from its planned principal
operations and is dependent upon significant financing to provide the
working capital necessary to execute its business plan. If the Company
determines that it is necessary to seek additional funding, there can b
'/>"/>
SOURCE XTL Biopharmaceuticals Ltd![]() Copyright©2007 PR Newswire. |